146 related articles for article (PubMed ID: 31553108)
1. Recontacting patients for multigene panel testing in hereditary cancer: Efficacy and insights.
Sawyer L; Creswick H; Lewandowski R; Quillin J
J Genet Couns; 2019 Dec; 28(6):1198-1207. PubMed ID: 31553108
[TBL] [Abstract][Full Text] [Related]
2. Recontact practices of cancer genetic counselors and an exploration of professional, legal, and ethical duty.
Mueller A; Dalton E; Enserro D; Wang C; Flynn M
J Genet Couns; 2019 Aug; 28(4):836-846. PubMed ID: 31058402
[TBL] [Abstract][Full Text] [Related]
3. Recontact to return new or updated
Panchal S; Mahajan R; Aujla N; McKay P; Casalino S; Di Gioacchino V; Charames GS; Lefebvre M; Metcalfe KA; Akbari MR; McCuaig JM; Lerner-Ellis J
J Med Genet; 2024 Apr; 61(5):477-482. PubMed ID: 38124008
[TBL] [Abstract][Full Text] [Related]
4. Patient and public preferences for being recontacted with updated genomic results: a mixed methods study.
Mighton C; Clausen M; Sebastian A; Muir SM; Shickh S; Baxter NN; Scheer A; Glogowski E; Schrader KA; Thorpe KE; Kim THM; Lerner-Ellis J; Kim RH; Regier DA; Bayoumi AM; Bombard Y
Hum Genet; 2021 Dec; 140(12):1695-1708. PubMed ID: 34537903
[TBL] [Abstract][Full Text] [Related]
5. Assessing the relationship between patient preferences for recontact after BRCA1 or BRCA2 genetic testing and their monitoring coping style in a Norwegian sample.
Dahle Ommundsen RM; Strømsvik N; Hamang A
J Genet Couns; 2022 Apr; 31(2):554-564. PubMed ID: 34716741
[TBL] [Abstract][Full Text] [Related]
6. Is there a duty to recontact in light of new genetic technologies? A systematic review of the literature.
Otten E; Plantinga M; Birnie E; Verkerk MA; Lucassen AM; Ranchor AV; Van Langen IM
Genet Med; 2015 Aug; 17(8):668-78. PubMed ID: 25503495
[TBL] [Abstract][Full Text] [Related]
7. Analysis of VUS reporting, variant reinterpretation and recontact policies in clinical genomic sequencing consent forms.
Vears DF; Niemiec E; Howard HC; Borry P
Eur J Hum Genet; 2018 Dec; 26(12):1743-1751. PubMed ID: 30143804
[TBL] [Abstract][Full Text] [Related]
8. Recontacting in light of new genetic diagnostic techniques for patients with intellectual disability: Feasibility and parental perspectives.
Beunders G; Dekker M; Haver O; Meijers-Heijboer HJ; Henneman L
Eur J Med Genet; 2018 Apr; 61(4):213-218. PubMed ID: 29191497
[TBL] [Abstract][Full Text] [Related]
9. Recontact: a survey of current practices and BRCA1/2 testing in Japan.
Sakaguchi T; Tokutomi T; Yoshida A; Yamamoto K; Obata K; Carrieri D; Kelly SE; Fukushima A
J Hum Genet; 2023 Aug; 68(8):551-557. PubMed ID: 37072622
[TBL] [Abstract][Full Text] [Related]
10. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
11. Men's experiences of recontact about a potential increased risk of prostate cancer due to Lynch Syndrome: "Just another straw on the stack".
Rasmussen V; Forbes Shepherd R; Forrest LE; James PA; Young MA
J Genet Couns; 2019 Aug; 28(4):750-759. PubMed ID: 30969465
[TBL] [Abstract][Full Text] [Related]
12. Recontacting in medical genetics: the implications of a broadening knowledge base.
Doheny S
Hum Genet; 2022 May; 141(5):1045-1051. PubMed ID: 34459979
[TBL] [Abstract][Full Text] [Related]
13. Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program.
Hermel DJ; McKinnon WC; Wood ME; Greenblatt MS
Fam Cancer; 2017 Jan; 16(1):159-166. PubMed ID: 27401692
[TBL] [Abstract][Full Text] [Related]
14. Patient perspectives on variant reclassification after cancer susceptibility testing.
Halverson CME; Connors LM; Wessinger BC; Clayton EW; Wiesner GL
Mol Genet Genomic Med; 2020 Jul; 8(7):e1275. PubMed ID: 32329193
[TBL] [Abstract][Full Text] [Related]
15. Psychosocial Effects of Multigene Panel Testing in the Context of Cancer Genomics.
Hamilton JG; Robson ME
Hastings Cent Rep; 2019 May; 49 Suppl 1(Suppl 1):S44-S52. PubMed ID: 31268573
[TBL] [Abstract][Full Text] [Related]
16. Experts reflecting on the duty to recontact patients and research participants; why professionals should take the lead in developing guidelines.
Mitchell C; Ploem C; Retèl V; Gevers S; Hennekam R
Eur J Med Genet; 2020 Feb; 63(2):103642. PubMed ID: 30904667
[TBL] [Abstract][Full Text] [Related]
17. Practices and Views of US Oncologists and Genetic Counselors Regarding Patient Recontact After Variant Reclassification: Results of a Nationwide Survey.
Makhnoon S; Davidson E; Shirts B; Arun B; Shete S
JCO Precis Oncol; 2023 Jun; 7():e2300079. PubMed ID: 37384863
[TBL] [Abstract][Full Text] [Related]
18. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
19. "Out of the blue": A qualitative study exploring the experiences of women and next of kin receiving unexpected results from BRA-STRAP research gene panel testing.
Morrow A; Speechly C; Young AL; Tucker K; Harris R; Poplawski N; Andrews L; Nguyen Dumont T; Kirk J; Southey MC; Willis A
J Genet Couns; 2023 Oct; ():. PubMed ID: 37864663
[TBL] [Abstract][Full Text] [Related]
20. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
